# Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

> **NCT02441465** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 6 (actual)

## Conditions studied

- Malignant Melanoma, Cancer

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** 14C-Labeled Vemurafenib

## Key facts

- **NCT ID:** NCT02441465
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-13
- **Primary completion:** 2016-08-18
- **Final completion:** 2017-01-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441465, "Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02441465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*